Feasibility of Using Daily Home High-Flow Nasal Therapy in COPD Patients Following a Recent COPD Hospitalization

Gerard J. Criner, MD, Lii-Yoong H. Criner, RN, CRN, Sheril A. George, BS, RRT, Jiji K. Thomas, MBBS, Michael R. Jacobs, PharmD

Abstract

Rationale: High-flow nasal therapy (HFNT) has beneficial effects in patients hospitalized with acute hypoxemic respiratory failure. HFNT has not been extensively studied following hospitalization for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Objective: We explored the feasibility of conducting a multicentered trial to evaluate the use of HFNT to increase the time to next moderate/severe exacerbation in patients recently hospitalized for a COPD exacerbation. In this pilot study we measured the hours of home daily HFNT use, maximally tolerated flow rates and temperature, and side effects for a period of 90 days.

Methods: Patients were enrolled in a 90-day, open-labeled pilot study of HFNT to determine the safety and feasibility of home use for daily outpatient COPD management. Patients ≥ 40 years of age with prior hospitalization within the past 12 weeks for an AECOPD were enrolled. COPD was the primary diagnosis in all patients.

Results: Thirty patients presented for HFNT titration. Two dropped out; 1 after receiving a lung transplant and the other was lost to follow-up. The remaining 28 patients completed 90 days of HFNT. None withdrew from HFNT due to intolerance. Use of HFNT averaged 6.8 (2.1) hours daily.

Conclusions: Daily home HFNT for up to 3 months is feasible in COPD patients following hospitalization for AECOPD. Improvements observed in disease-specific quality of life, respiratory symptoms, and 6-minute walk distance suggest the need for a prospective multicenter controlled clinical trial.

Abbreviations: high-flow nasal therapy, HFNT; acute exacerbation of COPD, AECOPD; chronic obstructive pulmonary disease, COPD; fraction of inspired oxygen, \( \text{FiO}_2 \); oxygen, \( \text{O}_2 \); noninvasive ventilation, NIV; positive airway pressure, PAP; informed consent, IC; body mass index, BMI; Snoring-Tiredness-Observed apnea-high blood Pressure-high BMI-age-neck circumference-gender, STOPBang; blood oxygen saturation determined by pulse oximetry, \( \text{SpO}_2 \); modified Medical Research Council, mMRC; arterial oxygen saturation, \( \text{SaO}_2 \); COPD Assessment Test, CAT; St George’s Respiratory Questionnaire, SGRQ; 6-minute walk test, 6MWT; Global initiative for chronic Obstructive Lung Disease, GOLD; BMI-airway Obstruction-Dyspnea-Exercise capacity scale, BODE; standard deviation, SD; interquartile, IQR; partial pressure of oxygen, \( \text{PaO}_2 \); partial pressure of carbon dioxide, \( \text{PaCO}_2 \); scale of acidity of the blood, \( \text{pH} \); bicarbonate, \( \text{HCO}_3^- \); short-acting muscarinic antagonist, SAMA; short-acting beta2 agonist, SABA; long-acting muscarinic antagonist, LAMA; inhaled corticosteroid, ICS; long-acting beta2-agonist, LABA; standard error of the mean, SEM; visual analog scales, VAS

Funding Support: Funding, equipment, and supplies were provided by Fisher & Paykel Healthcare.

Date of Acceptance: October 28, 2021 | Published Online Date: November 4, 2021

Citation: Criner GJ, Criner L-YH, George SA, Thomas JK, Jacobs MR. Feasibility of using daily home high-flow nasal therapy in COPD patients following a recent COPD hospitalization. Chronic Obstr Pulm Dis. 2022;9(1):4-14. doi: https://doi.org/10.15326/jcopdf.2021.0236

Keywords:
high-flow nasal therapy; COPD; acute exacerbation of COPD; home care
Home High-flow Nasal Therapy in COPD

Acute exacerbations account for 68% of chronic obstructive pulmonary disease (COPD) total care costs in the United States; hospitalizations account for the majority of costs.1 COPD is the 3rd leading cause of rehospitalization; re-hospitalization is associated with significant morbidity and mortality and also increases costs.2 The Agency for Health Care Policy Research reported, in 2008, that 21% of U.S. COPD patients were readmitted within 30 days and in 85% of readmissions, COPD was the primary or secondary diagnosis.3 Although many drug therapies prevent COPD exacerbations, as of yet, none primarily reduce mortality rates.2,4 Therapies that reduce ventilatory workload, are well tolerated, and easy to implement are needed as treatments for patients with COPD, especially in patients at risk for repeated hospitalization.

High flow nasal therapy (HFNT) is an approach that may help manage patients with COPD at risk for repeated exacerbations, especially those at risk for repeated hospitalization. HFNT delivers warmed, humidified air-oxygen blends with flow rates up to 60L/min with fraction of inspired oxygen (FiO2) from 21%–100%. HFNT enhances oxygenation by closely matching the patient’s inspiratory flow rate and minimizing ambient air entrainment during spontaneous breathing.5 Because of its higher flow rate, HFNT washes out nasopharyngeal dead space,6 improves ventilation efficiency,7 and provides a small but incremental flow-based increase in positive airway pressure.8 These are associated with an increase in end-inspiratory lung volume, reduced airway resistance, and increased functional residual capacity.9,10 HFNT has been reported to be better tolerated than standard nasal oxygen therapy because the delivered warmed, humidified gases reduces airway cooling and desiccation and may, thereby, moisten secretions and facilitate mucociliary clearance.11,12

Clinical trials using HFNT in acute hypoxemic respiratory failure have shown HFNT to be superior to oxygen (O2) or noninvasive ventilation (NIV) in ventilator free days and 90-day mortality13 and non-inferior to NIV in preventing reintubation after cardiothoracic surgery.14 HFNT has been reported superior to O2 in decreasing reintubation in critically ill patients at risk for reintubation,15 and reducing hospitalization stays following thoracic resection.16 HFNT improves oxygenation for the same level of FiO2 compared to a Venturi mask but with better patient comfort, fewer desaturations, less interface displacements, and a lower reintubation rate.17,18 In contrast to data about HFNT use in the above patient populations, data about its use in patients with COPD in the outpatient setting is limited.19-22 The mechanisms of potential benefit in this population have been described,23 but home use of HFNT is not available. The success of any clinical trial is largely driven by site investigators’ resources and capabilities, and the willingness of study participants to complete all study-related procedures and adhere to the proposed intervention. With that in mind, we performed a single-center study of HFNT use that incorporated many of the procedures and interventions that might be used in a multicentered trial to determine study feasibility. In this 90-day pilot study we measured the hours of daily HFNT use, the ranges of maximally tolerated flow rates and temperature, as well as any side effects that resulted in poor tolerance or termination of HFNT use.

Methods

Study participants were recruited from the pulmonary care unit of the Ambulatory Care Center of Temple University Hospital. Eligibility requirements were age ≥40 years and hospital admission for an acute exacerbation of COPD (AECOPD) within the past 12 weeks. All patients had to have recovered from their COPD exacerbation and be clinically stable. Patients must have had COPD as the primary diagnosis and have smoked ≥10 pack years. The main exclusion criteria were upper airway or nasal complications that prohibited the use of HFNT. Patients using any positive airway pressure (PAP) therapy (e.g., continuous-PAP or non-invasive positive-pressure ventilation) ≤4 weeks before study entry were excluded. Women of childbearing potential had a urine pregnancy test to ensure that they were not pregnant. Patients provided informed consent and expressed a willingness to participate in all study-related activities.
**Study Design**

The overall trial design is presented in Figure 1. Patients who met eligibility criteria and provided informed consent were scheduled for an outpatient visit. Prior to any other study-related procedures, patients were screened for a high likelihood of sleep apnea:

- Snoring-Tiredness-Observed apnea-high blood Pressure-Body mass index (BMI)-age-neck circumference-gender questionnaire (STOPBang)\(^24\) scores ≥5 or STOPBang score ≥2 plus BMI>35 kg/m\(^2\) or
- Berlin questionnaire scores suggesting a high likelihood of sleep apnea with increased risk of sleep-related accidents\(^25\) or
- excessive daytime sleepiness (i.e., either a high [>15] score on the Epworth Sleepiness Scale or a “fall asleep” accident or “near miss” accident in the prior 12 months).\(^26\)

**Intervention**

All study participants were asked to use the myAirvo™ 2 device (Fisher & Paykel Healthcare) for a minimum of 4 hours per night. The myAirvo™ 2 device is a humidifier with an integrated flow generator that delivers high-flow, warmed, and humidified respiratory gases to spontaneously breathing patients. The flow rate was initially set at 25L/min and titrated upward to maintain a blood oxygen saturation determined by pulse oximetry (SpO\(_2\)) of 90% or more at a temperature of 34°-37°C. Airflow was delivered
through the Optiflow™+ nasal cannula (Fisher & Paykel Healthcare) sized for patient comfort.

**Measurements**

Demographic data including age, gender, race, current medications, and comorbid conditions was collected at enrollment. At the baseline visit, vital signs were obtained as were dyspnea scores (modified Borg score, modified Medical Research Council [mMRC] dyspnea score). Arterial blood gases (ABG) after 5 minutes of inspiring supplemental oxygen to keep arterial oxygen saturation (SaO₂) > 90% were collected as well as the use of accessory muscles of ventilation. Pre- and post-bronchodilator spirometry was performed. Patients completed the COPD Assessment Test (CAT), and the St George’s Respiratory Questionnaire (SGRQ). Patients performed a 6-minute walk test (6MWT). The patient’s Global initiative for chronic Obstructive Lung Disease (GOLD) grade was determined and Body mass index-airway Obstruction-Dyspnea-Exercise (BODE) scores were calculated. For the primary outcome of patient comfort, a 100mm visual analog scale was used and anchored at 0 (no discomfort) and 100 (maximal imaginable discomfort). A 5-point Likert scale was used for patients to report their sensation of shortness of breath from “marked deterioration” to “marked improvement.” Patient comfort and sensation of shortness of breath were recorded at the baseline visit and at each of 5 subsequent clinic visits. Based on these reports, changes were made to flow rates and temperatures as needed.

Patients were provided with an electronic daily COPD symptom diary to record breathlessness, cough, consistency and quantity of sputum production, and the presence of wheezing, sore throat, or nasal congestion as well as daily peak flow readings. Patients were provided with a PersonalBest® (Philips Respironics) peak flow meter and asked to make 3 peak flow maneuvers. The best of the 3 maneuvers was recorded on the electronic symptom diary.

After a 2-week run-in period for symptom reporting, the patient returned to initiate HFNT therapy. Follow-up clinic visits and telephone contacts are shown in Figure 1.

At the conclusion of the study patients were offered the opportunity to continue to use HFNT therapy if they wished to do so.

**Sample Size**

This pilot study was powered to detect an unacceptably high rate of safety issues or unforeseen problems. The sample size was estimated based on the method described by Viechtbauer et al for detecting problems that arise in pilot studies. Using a 95% confidence threshold and 10% probability that a safety event occurred (defined as the need to discontinue HFNT due to intolerance) the required sample size was 29 patients.

**Statistical Analysis**

Descriptive statistics (mean [standard deviation (SD)] or median [interquartile range (IQR)]) are reported for continuous variables to characterize the patient population in terms of demographic factors and severity of airflow obstruction. Changes in arterial blood gases, 6MWT, CAT and SGRQ scores, and spirometry values were analyzed using paired t-tests. All tests were performed using JMP® Pro 14.2.0, © 2018 SAS Institute Inc.

**Study Conduct, Approval, and Registration**

This trial was conducted in accordance with the Declaration of Helsinki principles. The study protocol was approved by the Western Institutional Review Board (Approval Number: 20170689), and written informed consent was obtained from all study participants before they entered the trial. This trial was registered with ClinicalTrials.gov (NCT03221387) prior to the enrollment of the first study participant.

**Funding Source**

Fisher & Paykel Healthcare contributed towards the funding for this study.

**Results**

Forty-one patients who were recently hospitalized for a COPD exacerbation were consented for the
study (Figure 2). Two of these were subsequently excluded because of a high risk of having sleep apnea (by questionnaire) and 1 by a sleep study that revealed sleep apnea. Eight patients did not return for the high-flow titration visit and did not receive study intervention. Two patients who did start high-flow therapy subsequently dropped out before the end of the 90-day evaluation visit (1 received a lung transplant and another was lost to follow-up).

This report reflects the findings of the 28 patients who completed the 90-day visit. Baseline characteristics of the study participants are presented in Table 1.

### Nasal High Flow parameters

HFNT was delivered at 35 LPM in 24 patients and 30 LPM in 4 patients. Prior to the application of HFNT, 16 patients (57%) maintained adequate oxygen saturations with an FiO₂ of 21% (room air). The remaining 12 patients required supplemental oxygen with FiO₂ ranging between 26% and 32%. No changes were made to the oxygen prescription after application of the device. All patients left the oxygen titration visit with heated humidified high flow at 37°C. One patient subsequently asked that the temperature be reduced to 34°C at a follow-up visit.

### Table 1. Demographic and Baseline Data

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>69.2 (9.6)</td>
</tr>
<tr>
<td>Male sex (number, %)</td>
<td>15, 53.6%</td>
</tr>
<tr>
<td>Race White/Black/Declined (number, %)</td>
<td>14 (50%); 13 (46%); 1 (3.5%)</td>
</tr>
<tr>
<td>Smoking (pack years median (IQR))</td>
<td>43 (28 – 60)</td>
</tr>
<tr>
<td>BMI mean kg/m²</td>
<td>25.7 (4.3)</td>
</tr>
<tr>
<td>GOLD stage 2/3/4 (number, %)</td>
<td>1, 3.5% / 12, 42.6% / 15, 53.6%</td>
</tr>
</tbody>
</table>

#### Spirometry

- FVC, L: 1.90 (0.62)
- FEV₁, L: 0.75 (0.3)
- FEV₁/FVC: 0.39 (0.09)
- FEF 25-75, L: 0.27 (0.11)

#### mMRC N, %

<table>
<thead>
<tr>
<th>mMRC</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4, 14.3%</td>
</tr>
<tr>
<td>2</td>
<td>3, 10.7%</td>
</tr>
<tr>
<td>3</td>
<td>13, 46.4%</td>
</tr>
<tr>
<td>4</td>
<td>8, 28.6%</td>
</tr>
</tbody>
</table>

#### 6MWD

- 223 (76)

#### BORG

- 2.46 (1.56)

#### BODE Index

- 6.5 (1.8)

#### SGRQ (total score)

- 58.5 (12.9)

#### CAT

- 21.6 (7.9)

#### Arterial Blood Gases

- PaO₂ mmHg: 66 (11.3)
- PaCO₂ mmHg: 41.5 (5.8)
- pH: 7.44 (0.03)
- HCO₃ mEq/L: 27.5 (3.8)

#### Medication Combinations

- SAMA+SABA+LAMA: 1
- ICS+SABA: 4
- ICS+SABA+SAMA: 3
- ICS+SABA+LABA: 2
- ICS+SABA+SAMA+LABA: 2
- ICS+SABA+LABA+LAMA: 15
- ICS+SABA+SAMA+LABA+LAMA: 1

* N=28

Values are means (SD) except where noted.

BMI=body mass index; GOLD=Global Initiative for chronic Obstructive Lung Disease; FVC=forced vital capacity; FEV₁=forced expiratory volume in 1 second; FEF=forced expiratory flow; mMRC=modified Medical Research Council dyspnea score; 6MWD=6-minute walk distance; BODE=Body mass index-analy Obstruction-Dyspnea-Exercise capacity; SGRQ=St George’s Respiratory Questionnaire; CAT=COPD Assessment Test; PaO₂=partial pressure of oxygen; PaCO₂=partial pressure of carbon dioxide; pH=scale of acidity of the blood; HCO₃ bicarbonate; SAMA=short-acting muscarinic antagonist; SABA=short-acting beta₂ agonist; LABA=long-acting muscarinic antagonist; ICS=inhaled corticosteroid; LABA=long-acting beta₂ agonist
**Primary Outcomes**

Of the 30 patients initially enrolled in the study, 28 continued to use HFNT throughout the 90-day observation period.

Patients used HFNT for an average of 6.8 (SD 2.1) hours daily. Visual analog scores for patient comfort are shown in Figure 3. The scores among all patients averaged between 20mm and 30mm for each of the clinic visits although, there was substantial variability in scores, hence, they are reported as mean score±standard error of the mean (SEM) .

The effect of HFNT on the sensation of breathlessness tended to improve over the course of the study with 25 of 28 patients reporting a slight to marked improvement in the sensation of breathlessness by visits 4 and 5. (Table 2)

**Secondary Outcomes**

There were no statistically significant changes in any of the secondary outcomes, which included spirometry, arterial blood gases, 6MWT, SGRQ, and the CAT. (Table 3)

---

**COPD Symptom Reports**

COPD symptom reports showed that approximately 84% of all potential daily symptom reports (Figure 4) were made; median symptom reporting compliance was 85% (IQR 75%–93%). Trends for each of the COPD symptoms and peak flow readings are shown in Figure 5. Over the course of the 90-day study, only 7 reports of increased temperature were made by 6 different patients. Cough and wheezing were the most frequently reported COPD symptoms and tended to decrease over the study period. Nasal congestion and sore throat were less frequently reported, and the number of reports remained stable. Dyspnea scores remained unchanged. Average peak flow readings increased slightly during the reporting period from just over 200L/min to around 235L/min. Several changes were observed in the characteristics of sputum production. The number of patients who reported no sputum production trended upward over the course of the study with patients reporting decreases in thick, thin, and watery sputum consistency. Very few individuals reported production of green or brown sputum. The numbers of patients who produced white or yellow sputum decreased over time with the majority moving towards no sputum production.

---

**Discussion**

In our study of HFNT in patients recently discharged from the hospital for a COPD exacerbation, we met our primary objective of assessing the feasibility of daily use over 90 days. In this population of patients with very severe COPD and recent hospitalization, we found acceptable daily usage of HFNT at optimal HFNT settings of flow and humidification and no untoward side effects or technical issues. No patients who were started on HFNT needed to be removed for...
lack of efficacy or intolerance, although 2 patients dropped out: 1 after receiving a lung transplant and the other was lost to follow-up despite multiple attempted contacts. While we asked patients to use HFNT for a minimum of 4 hours daily, the overall daily use was greater than that and averaged about 6 hours per day. Patients agreed to and were able to complete all study-related assessments.

Pearson has defined comfort as a physical sensation, a psychological state, or a combination of both. Measurement of comfort is by definition, subjective. In a comparison study between nasal high-flow therapy and Venturi mask oxygen therapy by Maggiore, patients were asked about discomfort with the nasal interface and symptoms of airway dryness. This was done by using a 0 to 10 scale correlating with no discomfort and maximum discomfort respectively. Visual analog scales (VAS) have also been used. We utilized a 100mm VAS to assess patient discomfort while using the device. Mean VAS scores averaged near 30mm at the start of the study and decreased over time; however, there

### Table 3. Secondary Outcomes

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Baseline</th>
<th>Visit 5</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVC, L</td>
<td>1.90 (0.62)</td>
<td>1.97 (0.57)</td>
<td>0.33</td>
</tr>
<tr>
<td>FEV₁, L</td>
<td>0.75 (0.3)</td>
<td>0.75 (0.3)</td>
<td>0.93</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>0.39 (0.09)</td>
<td>0.38 (0.09)</td>
<td>0.22</td>
</tr>
<tr>
<td>FEF 25-75, L</td>
<td>0.27 (0.11)</td>
<td>0.27 (0.11)</td>
<td>0.85</td>
</tr>
<tr>
<td>6MWD</td>
<td>223 (76.5)</td>
<td>247 (81.6)</td>
<td>0.18</td>
</tr>
<tr>
<td>BORG</td>
<td>2.46 (1.56)</td>
<td>2.39 (1.27)</td>
<td>0.67</td>
</tr>
<tr>
<td>SGRQ (total score)</td>
<td>58.5 (12.9)</td>
<td>55.1 (11.6)</td>
<td>0.13</td>
</tr>
<tr>
<td>CAT</td>
<td>21.6 (7.9)</td>
<td>19.0 (7.5)</td>
<td>0.07</td>
</tr>
</tbody>
</table>

Arterial Blood Gases

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>Visit 5</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaO₂ mmHg</td>
<td>66 (11.3)</td>
<td>68 (15.2)</td>
<td>0.44</td>
</tr>
<tr>
<td>PaCO₂ mmHg</td>
<td>41.5 (5.8)</td>
<td>41.5 (5.4)</td>
<td>0.57</td>
</tr>
<tr>
<td>pH</td>
<td>7.44 (0.03)</td>
<td>7.44 (0.02)</td>
<td>0.75</td>
</tr>
<tr>
<td>HCO₃ mEq/L</td>
<td>27.5 (3.8)</td>
<td>27.4 (3.4)</td>
<td>0.79</td>
</tr>
</tbody>
</table>

FVC=forced vital capacity; FEV₁=forced expiratory volume in 1 second; FEF=forced expiratory flow; 6MWD=6-minute walk distance; SGRQ=St George’s Respiratory Questionnaire; CAT=COPD Assessment Test; PaO₂=partial pressure of oxygen; PaCO₂=partial pressure of carbon dioxide; pH=scale of acidity of the blood; HCO₃=bicarbonate

### Figure 4. Daily Symptom Reports

- **Cough**: Number of patients reporting cough.
- **Dyspnea Score**: Median score over time.
- **Nasal congestion**: Number of patients reporting nasal congestion.
- **Sore Throat**: Number of patients reporting sore throat.
- **Sputum Color**: Distribution of sputum colors.
- **Sputum Consistency**: Distribution of sputum consistencies.
- **Sputum Quantity**: Distribution of sputum quantities.
- **Wheeze**: Number of patients reporting wheezing.
was substantial variability in the comfort scores even in the same patient between visits. When used for the assessment of pain, a score of 30mm or less is typically defined as “mild pain.” It appears that many patients experienced mild discomfort around the nares using the device at some point over the course of the study, though none discontinued using the device due to this mild discomfort.

Although there were no statistically significant differences in the secondary outcomes, there was a 24-meter increase in 6-minute walk distance, and a 3.4-point drop in the SGRQ. The improvement in 6-minute walk distance parallels the observation in another controlled trial of HFNT versus usual care. Their same study showed a stabilization of the SGRQ in the HFNT group compared to a slight worsening in the usual care group. Despite being unpowered to reach this endpoint, our study also showed a 2.6-point drop in the CAT, which just failed to reach statistical significance ($p=0.07$).

Most of the symptom scores reported in the daily electronic diary remained essentially unchanged over the study including nasal congestion, Borg dyspnea score, presence of sore throat, and peak flow readings. What did trend downward were the number of reports of wheezing and cough, and changes in the color, consistency, and volume of sputum. Patients who produced white or yellow sputum transitioned to none; those producing thick or thin sputum transitioned to watery or no sputum production; and those who were producing a tablespoonful or more of sputum daily transitioned to no or lower levels of sputum production. The reasons for the shift to no or lower levels of sputum production are not known but the application of heated and humidified HFNT has been reported to facilitate secretion removal. It may be that HFNT users find it easier to cough and clear secretions, but this was not objectively measured in our pilot study. A recent study by Choate and colleagues shows that those who experience more cough and sputum production have worse clinical and quality of life outcomes. Even so, there is no evidence to suggest that reducing cough or altering the volume, consistency, or color of sputum results in improvements in clinical or quality of life measures. Our study was not powered to show improvements in these outcomes.

By study’s end, 25 of 28 patients reported a slight to marked improvement in the sensation of breathlessness. This occurred even though there were no measurable changes in the Borg dyspnea scale, daily peak flow measures, arterial blood gases, or spirometry, which suggests that factor(s) other than dyspnea may be represented by this measurement. The finding of improvement in the sensation of breathlessness is consistent with a report of the qualitative experiences of domiciliary HFNT users and their relatives obtained by Storgaard. Her structured interviews identified 6 themes that related to therapy adherence. These included: a perceived lower work of breathing, reduced COPD symptoms, improvement in sleep quality, increased activity of daily living, feeling safe, and technology use. Perhaps a reduction in respiratory rate in patients with severe obstruction when using HFNT resulted in a prolongation of expiratory time and decrease in the extent of air-trapping, a known consequence of severe exacerbation in patients hospitalized with a COPD exacerbation. Further studies will need to measure the impact of HFNT on air trapping.

**Limitations**

This study has several limitations. First, as a feasibility study the number of enrolled patients was small and performed at a single clinical center. Second, all patients were assigned to the intervention and served as their own control. Third, the use of the VAS and Likert scale to assess the sensation of shortness of breath have not been validated.
Conclusions

This single center study demonstrates the feasibility of using daily home HFNT in COPD patients recently discharged from the hospital for a COPD exacerbation. The therapy was well tolerated, and no patient needed to be removed from the intervention. The trends for improvements in quality of life measured by SGRQ, the CAT, and 6-minute walk distance suggests that home HFNT may have benefit in patients following a recent COPD hospitalization. These findings require validation by a well-powered, prospective, multicentered, controlled trial.

Acknowledgements

Author contributions: GJC, LHC, and MRJ formulated the overall study design. LHC, SG, and JKT assisted in data collection and consolidation. MRJ performed statistical analysis. MRJ and LHC drafted the manuscript. GJC reviewed and revised the manuscript. All authors reviewed and approved final manuscript for submission and publication.

Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declaration of Interest

GJC has received grant funding from Fisher & Paykel. JKT, MRJ, SAG, and LHC have no conflicts of interest.
References


37. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form Mcgill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis Care Res*. 2011;63(S11):S240-S52. doi: https://doi.org/10.1002/acr.20543


